Trial Profile
A Phase II, Single-arm Study of Docetaxel and Oxaliplatin in Metastatic Cisplatin-resistant Transitional Cell Carcinoma of the Urinary Bladder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Aug 2017
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Oxaliplatin (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 22 May 2017 New trial record